Vice President, Investor Relations and Corporate Communications; Sylvia Wheeler
Ms. Wheeler will lead Hyperion's strategic external communications initiatives with the investment and media communities. Ms. Wheeler joins the team from Affymax, Inc. a biopharmaceutical company where she most recently served as vice president, Corporate Communications. Prior to joining Affymax in 2007, Ms. Wheeler served as senior director, Corporate Communications for Depomed, Inc., a specialty pharmaceutical company. Ms. Wheeler has also served in similar functions at Cerus Corporation, a biomedical products company, Coulter Pharmaceuticals, Inc. a biotechnology company and at Russell Welsh, a communications agency focused exclusively on the bioscience industry. Ms. Wheeler earned her M.B.A from the University of San Francisco and a B.A. in Biology from San Francisco State University.
About Hyperion Therapeutics
Hyperion Therapeutics, Inc. is a commercial stage biopharmaceutical company committed to developing and delivering life-changing treatments for orphan diseases and hepatology. The company's first commercial product, Ravicti® (glycerol phenylbutyrate) Oral Liquid, was approved in February 2013 and is currently being marketed in the United States. The company also owns and markets BUPHENYL® (sodium phenylbutyrate) Tablets and Powder worldwide. For more information, please visit www.hyperiontx.com .
CONTACT: Sylvia Wheeler, Investor Relations (650) 794-7834